Cargando…

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models

Elevated expression of multiple growth factors and receptors including c‐Met and VEGFR has been reported in gastric adenocarcinoma (GAC) and thus provides a potentially useful therapeutic target. The therapeutic efficacy of foretinib, a c‐Met/VEGFR2 inhibitor, was determined in combination with nano...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grojean, Meghan, Schwarz, Margaret A., Schwarz, Johann R., Hassan, Sazzad, von Holzen U, Zhang, Changhua, Schwarz, Roderich E., Awasthi, Niranjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178268/ https://www.ncbi.nlm.nih.gov/pubmed/33939252 http://dx.doi.org/10.1111/jcmm.16362

Ejemplares similares

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2017)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models
por: Awasthi, Niranjan, et al.
Publicado: (2016)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
por: Hassan, Md Sazzad, et al.
Publicado: (2023)

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2017)

Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer
por: Awasthi, Niranjan, et al.
Publicado: (2012)

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
por: Awasthi, Niranjan, et al.
Publicado: (2013)

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
por: Awasthi, Niranjan, et al.
Publicado: (2023)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2021)

Therapeutic efficacy of anti‐MMP9 antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical models of pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2019)

Cytokine Interaction With Cancer-Associated Fibroblasts in Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2022)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Cell Proliferation and Migration Are Modulated by Cdk-1-Phosphorylated Endothelial-Monocyte Activating Polypeptide II
por: Schwarz, Margaret A., et al.
Publicado: (2012)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2021)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2022)

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2011)

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Publicado: (2022)

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
por: Chen, Hsiu-Mei, et al.
Publicado: (2015)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

56. Foretinib Enhances Myelination of Neurons in Vitro
por: Mirmoeini, Kaveh, et al.
Publicado: (2023)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

National Economic Conditions May Impact the Financial Barriers to Travel for Cancer Operations
por: Henry, Leonard R., et al.
Publicado: (2023)

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts
por: Bozec, A, et al.
Publicado: (2007)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Foretinib mitigates cutaneous nerve fiber loss in experimental diabetic neuropathy
por: Daeschler, Simeon C., et al.
Publicado: (2022)

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
por: Ji, Xiwei, et al.
Publicado: (2023)

Blockade of VEGFR-1 and VEGFR-2 Enhances Paclitaxel Sensitivity in Gastric Cancer Cells
por: Hwang, Jun-Eul, et al.
Publicado: (2013)

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018)

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
por: Zhang, Yu, et al.
Publicado: (2018)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
por: Koustas, Evangelos, et al.
Publicado: (2020)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ju56n6rh91sr9s52p11rrfudlt